Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in the United States
Top Cited Papers
- 1 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Cardiovascular Interventions
- Vol. 13 (3), e008425
- https://doi.org/10.1161/circinterventions.119.008425
Abstract
Background: Transcatheter mitral valve replacement using aortic transcatheter heart valves has recently become an alternative for patients with degenerated mitral bioprostheses, failed surgical repairs with annuloplasty rings or severe mitral annular calcification who are poor surgical candidates. Outcomes of these procedures are collected in the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. A comprehensive analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR), and valve-in-mitral annular calcification (ViMAC) outcomes has not been performed. We sought to evaluate short-term outcomes of early experience with MViV, MViR, and ViMAC in the United States. Methods: Retrospective analysis of data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Results: Nine hundred three high-risk patients (median Society of Thoracic Surgeons score 10%) underwent MViV (n=680), MViR (n=123), or ViMAC (n=100) between March 2013 and June 2017 at 172 hospitals. Median age was 75 years, 59.2% female. Technical and procedural success were higher in MViV. Left ventricular outflow tract obstruction occurred more frequently with ViMAC (ViMAC=10%, MViR=4.9%, MViV=0.7%; PP=0.004) and 30-day mortality (MViV=8.1%, MViR=11.5%, ViMAC=21.8%; P=0.003) were higher in ViMAC. At 30-day follow-up, median mean mitral valve gradient was 7 mm Hg, most patients (96.7%) had mitral regurgitation grade ≤1 (+) and were in New York Heart Association class I to II (81.7%). Conclusions: MViV using aortic balloon-expandable transcatheter heart valves is associated with a low complication rate, a 30-day mortality lower than predicted by the Society of Thoracic Surgeons score, and superior short-term outcomes than MViR and ViMAC. At 30 days, patients in all groups experienced improvement of symptoms, and valve performance remained stable. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02245763. Download figure Download PowerPointKeywords
This publication has 22 references indexed in Scilit:
- Transcatheter Mitral Valve Replacement in Native Mitral Valve Disease With Severe Mitral Annular CalcificationJACC: Cardiovascular Interventions, 2016
- Predicting LVOT Obstruction After TMVRJACC: Cardiovascular Imaging, 2016
- Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitionsEuropean Heart Journal, 2015
- Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 2: Endpoint DefinitionsJournal of the American College of Cardiology, 2015
- The STS-ACC Transcatheter Valve Therapy National RegistryJournal of the American College of Cardiology, 2013
- Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experienceInteractive CardioVascular and Thoracic Surgery, 2012
- Standardized Endpoint Definitions for Transcatheter Aortic Valve Implantation Clinical TrialsJournal of the American College of Cardiology, 2011
- Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research ConsortiumEuropean Heart Journal, 2010
- Determinants of Hospital Mortality after Repeat Mitral Valve Surgery for Rheumatic Mitral Valve DiseaseThe Thoracic and Cardiovascular Surgeon, 2006
- Reoperation for Bioprosthetic Mitral Structural Failure: Risk AssessmentCirculation, 2003